Drugs / Oral Polio Vaccine (OPV)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05155579 | May 2022 → May 2025 | malaria | University of Oxford | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02961595 Comparator | Oct 1999 → Nov 2016 | enterovirus infectious disease, prediabetes syndrome, type 1 diabetes mellitus | Tampere University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oral Polio Vaccine (OPV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02961595 ↗ |
| Known as | Polio Sabin | “Sixty-four children (34 males) were given doses of OPV (Polio Sabin®, SB Biologicals, Rixensart, Belgium) at the age of 2, 3, 6 and 12 months during the years 1999-2000 (two...” NCT02961595 ↗ |
| Modality | Vaccine | “early serial live enterovirus vaccine (oral polio vaccine, OPV)” NCT02961595 ↗ |
| Route | Oral | “two drops per os in each dose” NCT02961595 ↗ |